调节性T细胞与变应性鼻炎特异性脱敏治疗效果的关系

doi:10.6040/j.issn.1673-3770.0.2014.189

摘要/Abstract

摘要： 目的探讨外周血Treg细胞和IL-10水平在变应性鼻炎患者不同疗程特异性脱敏治疗后的差异以及能否预测特异性脱敏治疗的疗效。方法收集变应性鼻炎(AR)患者60例，随机分配至不同疗程治疗组(12个月治疗组和24个月治疗组)。治疗前后采集外周血，用流式细胞仪检测外周血中Treg细胞(Foxp3⁺CD4⁺CD25⁺细胞)占外周血单核细胞的比例和酶联免疫分析试剂盒检测IL-10水平。结果 AR患者外周血Treg细胞百分比和IL-10水平明显低于正常对照组； AR患者在特异性脱敏治疗后,外周血Treg细胞百分比和IL-10水平较治疗前明显提高。相关分析提示外周血IL-10水平与Treg细胞百分比呈正相关性。24个月疗程脱敏治疗组比12个月疗程治疗组有效率更高，且24个月疗程患者治疗后其外周血Treg细胞百分比和IL-10水平明显高于12个月疗程组。脱敏治疗有效人群治疗后的IL-10水平明显高于治疗前，而治疗无效人群治疗前后的IL-10水平无统计学差异。结论外周血Treg细胞水平在一定程度上可以预测特异性脱敏治疗的疗效；24个月疗程脱敏治疗效果优于12个月疗程脱敏治疗。

关键词: 特异性脱敏治疗, 变应性鼻炎, 调节性T细胞

Abstract: Objective To explore the expression difference of the levels of Treg cells and IL-10 of patients with allergic rhinitis (AR) in serum in different courses of special immunotherapy treatment (SIT) and to explore whether the expressions can forecast the efficacy of SIT. Methods From January 2011, 30 patients with AR were randomly collected and distributed into the 12 months SIT group and the 24 months SIT group. The peripheral blood was taken before and after the SIT, and the expressions of Treg cells were measured by FCM and IL-10 were calculated by ELISA. Results The percentage of Treg cells and the level of IL-10 in the AR groups were significantly decreased compared with those of the control group; After SIT, the percentage of Treg cells and the level of IL-10 in serum were significantly increased than those before SIT. Correlation analysis showed IL-10 was positively related with Treg cells. The clinical efficacy of the 24 months SIT group were higher than that of the 12 months SIT group, and furthermore the percentage of Treg cells and the level of IL-10 in the 24 month SIT group were significantly higher than those in the 12 month SIT group. In effective group, IL-10 level increased significantly after the SIT treatment, while the level of IL-10 did not significantly change after the treatment in non-effective group. Conclusion The percentage of Treg cells in peripheral blood of patients with AR may be useful in predicting the efficacy of the SIT treatment. A 24-month course SIT treatment is better than a 12-month course SIT treatment.

Key words: Allergic rhinitis, Special immunotherapy treatment, T regulatory cell

中图分类号:

R765.21

于阅尽, 谭骏, 曹云虹, 张慧, 贾秀华, 叶青. 调节性T细胞与变应性鼻炎特异性脱敏治疗效果的关系[J]. 山东大学耳鼻喉眼学报, 2014, 28(5): 38-41.

YU Yue-jin, TAN Jun, CAO Yun-hong, ZHANG Hui, JIA Xiu-hua, YE Qing. Relationship between Treg cells in peripheral blood of patients with allergic rhinitis and special immunotherapy efficacy[J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2014, 28(5): 38-41.

参考文献

[1] Bousquet J I, Khaltaev N, Cruz A A,et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen) [J]. Allergy, 2008, 63 (1):8-160.
[2] El-Qutob D, Mencia G, Fernandez-Caldas E I. Recent advances in immunotherapy for allergic diseases[J]. Recent Pat Inflamm Allergy Drug Discov, 2014, 8(1):24-35.
[3] Cox L, Wallace D. Specific allergy immunotherapy for allergic rhinitis: subcutaneous and sublingual[J].Immunol Allergy Clin North Am, 2011, 31(3):561-99.
[4] Plewako H, Wosinska K, Arvidsson M, et al. Basophil interleukin 4 and interleukin 13 production is suppressed during the early phase of rush immunotherapy[J]. Int Arch Allergy Immunol, 2006, 141(4):346-353.
[5] James L K, Durham S R. Update on mechanisms of allergen injection immunotherapy[J]. Clin Exp Allergy, 2008, 38(7):1074-1088.
[6] 庞文会,时光刚,时蕾,等.调节性T细胞与IgE、IL-4、IL-5在变应性鼻炎小鼠和鼻用激素抗炎中的实验研究[J]. 山东大学耳鼻喉眼学报,2013,27(2)：29-33. PANG Wenhui, SHI Guanggang, SHI Lei, et al. Experimental study on regulatory T cells and IgE,IL-4 and IL-5 in a mouse model of allergic rhinitis and in administration of nasal corticosteroid [J]. J Otolaryngol Ophthalmol Shandong University, 2013, 27(2)：29-33.
[7] Akidis M, Verhagen J, Taylor A, et al. Immune responses in healthy and allergic individuals are characterized by a fine balance between al-lergic-specific T regulatory l and T helper 2 cells[J]. J Exp Med, 2004, 199(11):1567-1575.
[8] Ling E M, Smith T, Nguyen X D,et al. Relation of CD4⁺CD25⁺ regulatory T cell suppression of allergen-driven T cell activation to atopic status and expression of allergic disease[J]. Lancet, 2004, 363(9409):608-615.
[9] Xu G, Mou Z, Jiang H, et al. A possible role of CD4⁺CD25⁺ T cells as well as transcription factor Foxp3 in the dysregulation of allergic rhinitis[J]. Laryngoscope, 2007,117(5):876-880.
[10] 余少卿,陈英剑,章捷,等.CD4⁺CD25⁺调节性T细胞在变应性鼻炎患者外周血淋巴细胞中的含量研究[J].临床耳鼻咽喉头颈外科杂志,2011,25(8):354-355, 359. YUShaoqing,CHENYingjian,ZHANGJie, et al. ContentofCD4^＋CD25^＋regulatoryTcellsinperipheralblood lymphocytesinpatientswithallergicrhinitis[J]. J Clin Otorhinolaryngol Head Neck Surgery, 2011, 25(8):354-355, 359.
[11] Francis J N, Till S J, Durham S R. Induction of IL-10⁺CD4⁺CD25⁺ T cells by grass pollen immunotherapy[J]. J Allergy Clin Immunol, 2003, 111(6):1255- 1261.
[12] Francis J N, James L K, Paraskevopoulos G, et al. Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity[J]. J Allergy Clin Immunol, 2008, 121(5):1120-1125.
[13] Shevach E M I, DiPaolo R A, Andersson J,et al. The lifestyle of naturally occurring CD4⁺ CD25⁺ Foxp3⁺ regulatory T cells [J].Immunol Rev, 2006, 212(1):60-73.

相关文章 15

[1]	吕倩,唐源,顾子君,施赛磊,刘萍,万文锦. 变应性鼻炎患者疾病获益感现状及影响因素分析[J]. 山东大学耳鼻喉眼学报, 2026, 40(1): 21-28.
[2]	顾敏,陆美萍. 纳米药物输送系统在变应性鼻炎过敏原免疫治疗中的应用进展[J]. 山东大学耳鼻喉眼学报, 2026, 40(1): 106-111.
[3]	秦娜娜,李玉芬,孙雨浩,魏健,李钦. 基于TGF-β1/Smad信号通路探讨白细胞介素13受体α2对变应性鼻炎大鼠鼻黏膜组织重塑的影响[J]. 山东大学耳鼻喉眼学报, 2025, 39(6): 71-77.
[4]	熊琴, 张砚, 乌日娜, 李锋, 唐力行. 鼻用糖皮质激素在儿童中的应用[J]. 山东大学耳鼻喉眼学报, 2025, 39(6): 160-167.
[5]	许雪萌,樊磊,喻望博,蒋芝月,潘晨,黄泳芹. 奥马珠单抗联合特异性免疫治疗变应性鼻炎疗效的Meta分析[J]. 山东大学耳鼻喉眼学报, 2025, 39(5): 26-33.
[6]	刘怡君,谷悦,官大宇,杨玉成,沈暘. 翼管神经切断术在难治性变应性鼻炎中远期临床疗效和安全性[J]. 山东大学耳鼻喉眼学报, 2025, 39(5): 42-48.
[7]	张婷,王美兰,高映勤. 白细胞介素35在变应性鼻炎中的研究进展[J]. 山东大学耳鼻喉眼学报, 2025, 39(5): 139-147.
[8]	张竹萍,彭孜灿,肖振龙,李程,喻迪,王兴龙,陈伟,郭蓓. 新型鼻分泌物嗜酸粒细胞阳离子蛋白-髓过氧化物酶试纸在变应性鼻炎中的应用价值[J]. 山东大学耳鼻喉眼学报, 2025, 39(3): 129-134.
[9]	刘畅,杨景朴,高雨,王文佳. 长春地区儿童变应性鼻炎变应原检测结果分析[J]. 山东大学耳鼻喉眼学报, 2025, 39(2): 51-58.
[10]	周荷青,申琪. 中医药治疗变应性鼻炎疗效的生物标志物研究进展[J]. 山东大学耳鼻喉眼学报, 2025, 39(2): 168-176.
[11]	王曼娴,郑泉,杨亮. 细菌裂解物治疗变应性鼻炎的研究进展[J]. 山东大学耳鼻喉眼学报, 2025, 39(1): 141-145.
[12]	刘畅,方宏艳,刘敩,富东娜,王贺,王晶,杨景朴. 长春地区秋季变应性鼻炎蒿属花粉致敏特征分析[J]. 山东大学耳鼻喉眼学报, 2024, 38(5): 13-19.
[13]	朱朗,刘志奇. 移动医疗提供的真实世界数据在变应性鼻炎治疗方案中的参考[J]. 山东大学耳鼻喉眼学报, 2024, 38(4): 135-139.
[14]	张静祎,董湘依,牟亚魁,宋西成. 细胞焦亡在耳鼻咽喉科疾病中的研究进展[J]. 山东大学耳鼻喉眼学报, 2024, 38(4): 140-148.
[15]	张丽净,冯晓星,刘南仙,赵辉明,陈月华. 石墨烯养护鼻罩结合尘螨的皮下特异性免疫治疗在尘螨变应性鼻炎患者中的应用分析[J]. 山东大学耳鼻喉眼学报, 2024, 38(3): 26-32.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed